https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-savvas-stavrinos-270619-814544-1030x686-1.jpg6861030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-06 10:37:272026-01-06 10:37:27Servier and Insilico sign an $888 million AI oncology discovery deal
https://european-biotechnology.net/wp-content/uploads/2025/12/MFN9.webp359800Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-22 08:17:232025-12-22 08:17:23Nine Big Pharma to cut US drug prices in Most-favoured Nations deals
https://european-biotechnology.net/wp-content/uploads/2025/12/Clarivate-e1766397076442-1030x443-1.png4431030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-20 09:49:162025-12-20 09:49:16Trump Administration tables new version of Biosecure Act
https://european-biotechnology.net/wp-content/uploads/2025/12/FDA-White-Oak-Building-01.jpg220420Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-19 10:41:062025-12-19 10:41:06Egetis Therapeutics AB submits rolling NDA for tiratricol
https://european-biotechnology.net/wp-content/uploads/2025/12/Thanos-Halazonetis-scaled-e1766052380320-1030x581-1.png5811030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-18 10:09:392025-12-18 10:09:39FoRx raises US$50m in Series A to advance PARG inhibitor
https://european-biotechnology.net/wp-content/uploads/2025/12/Sam-Possemiers-in-Lab_-Christophe-De-Muynck-2-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-18 08:54:212025-12-18 08:54:21Belgian microbiome player MRM Health initiates R&D partnership in cancer immunotherapy
